Neuren receives U$50m boost from FDA voucher sale
Neuren Pharmaceuticals (ASX:NEU) is set to receive a substantial payout following the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its US-based partner, Acadia Pharmaceuticals (NASDAQ: ACAD), for $US150m. Under the agreement, Neuren will receive one-third of the net proceeds, estimated to be approximately $US50m. The PRV was issued by the US […]
Neuren receives U$50m boost from FDA voucher sale Read More »